Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.
Targeted airway delivery of antifungals as prophylaxis against invasive aspergillosis may lead to high lung drug concentrations while avoiding toxicities associated with systemically administered agents. We evaluated the effectiveness of aerosolizing the intravenous formulation of voriconazole as prophylaxis against invasive pulmonary aspergillosis caused by Aspergillus fumigatus in an established murine model. Inhaled voriconazole significantly improved survival and limited the extent of invasive disease, as assessed by histopathology, compared to control and amphotericin B treatments.
Tolman
Justin A
JA
The University of Texas at Austin College of Pharmacy, Austin, Texas, USA.
Wiederhold
Nathan P
NP
McConville
Jason T
JT
Najvar
Laura K
LK
Bocanegra
Rosie
R
Peters
Jay I
JI
Coalson
Jacqueline J
JJ
Graybill
John R
JR
Patterson
Thomas F
TF
Williams
Robert O
RO
D000280:Administration, Inhalation; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D055744:Invasive Pulmonary Aspergillosis / Q000517:prevention & control*; D051379:Mice; D008813:Mice, Inbred ICR; D011743:Pyrimidines / Q000008:administration & dosage*; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole